Publications by authors named "Karan S Dixit"

Purpose: Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers.

View Article and Find Full Text PDF
Article Synopsis
  • There is a significant need for new treatments for glioblastoma (GBM), and acetazolamide has shown promise in enhancing the effectiveness of the existing treatment, temozolomide (TMZ), by addressing resistance mechanisms.
  • This phase I trial involved 24 patients with high-grade gliomas, administering acetazolamide alongside TMZ, and observed no dose-limiting toxicities while monitoring common side effects.
  • Results indicated a median overall survival of about 30 months for GBM patients, with a notable survival rate that suggests acetazolamide could be beneficial, warranting further investigation in randomized trials and highlighting BCL-3 expression as a potential prognostic marker.
View Article and Find Full Text PDF

Purpose: Histone 3 (H3) K27M-mutant diffuse midline glioma (DMG) has a dismal prognosis with no established effective therapy beyond radiation. This integrated analysis evaluated single-agent ONC201 (dordaviprone), a first-in-class imipridone, in recurrent H3 K27M-mutant DMG.

Methods: Fifty patients (pediatric, n = 4; adult, n = 46) with recurrent H3 K27M-mutant DMG who received oral ONC201 monotherapy in four clinical trials or one expanded access protocol were included.

View Article and Find Full Text PDF

Background: Primary central nervous system lymphoma (PCNSL) is a rare, often curable neoplasm, often initially presenting in acute care settings by nonneuroscience specialized physicians. Delays in the recognition of specific imaging findings, lack of appropriate specialist consultation, and urgent incorrect medication administration can delay necessary diagnosis and treatment.

Review Summary: In this paper, the reader is moved quickly from the initial presentation to the diagnostic surgical intervention for PCNSL in a manner analogous to the experience of clinicians in the frontline setting.

View Article and Find Full Text PDF

Stroke-like migraine attacks after radiation therapy (SMART) syndrome is a rare, delayed complication of cranial radiation therapy that consists of migraine-like headaches and focal neurologic deficits such as visual loss, aphasia, hemiparesis, hemisensory loss, and unconsciousness. SMART syndrome may be mistaken for tumor recurrence, radiation necrosis, and stroke. Timely recognition of SMART syndrome prevents unnecessary brain biopsies and enables appropriate anticipatory guidance.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to improve survival for high-grade glioma patients who didn’t respond to standard treatments by testing a combination of re-irradiation, bevacizumab, and temozolomide.
  • A total of 54 patients participated, primarily consisting of those previously treated with bevacizumab, and results showed a median overall survival of 8.5 months, with better outcomes for patients further from their initial radiation.
  • The treatment was generally well tolerated with minimal severe side effects, and it may provide a viable option for patients with recurrent gliomas.
View Article and Find Full Text PDF

Corticosteroids have been essential in the management of brain tumor patients for decades, primarily for the treatment of peritumoral cerebral edema and its associated neurologic deficits. Dexamethasone is the drug of choice with standard practice being administration up to four times per day, however, because of its long biologic half-life and high potency, once or twice a day dosing is likely adequate in patients without elevated intracranial pressure. The length of corticosteroid treatment should be limited to the shortest period of time to minimize the risk of potential toxicities that can significantly affect quality of life, as well as to avoid a possible detrimental impact on survival in high-grade glioma patients and abrogation of the effect of immunotherapy.

View Article and Find Full Text PDF

Central nervous system (CNS) metastasis from systemic cancers can involve the brain parenchyma, leptomeninges (pia, subarachnoid space and arachnoid mater), and dura. Leptomeningeal metastases (LM), also known by different terms including neoplastic meningitis and carcinomatous meningitis, occur in both solid tumors and hematologic malignancies. This review will focus exclusively on LM arising from solid tumors with a goal of providing the reader an understanding of the epidemiology, pathophysiology, clinical presentation, prognostication, current management and future directions.

View Article and Find Full Text PDF

Background: Progress in extending the survival of glioblastoma (GBM) patients has been slow. A better understanding of why patient survival remains poor is critical to developing new strategies. Postmortem studies on GBM can shed light on why patients are dying.

View Article and Find Full Text PDF

Treating patients with brain tumors can be divided into tumor-directed therapies, the management of tumor-related symptoms and complications and the psychosocial aspect of patient care. In this review, we will discuss the management of disease and treatment-related complications, which can negatively impact patient quality of life and functional status. Brain edema is a common complication or brain tumors and often causes more symptoms than the tumor itself.

View Article and Find Full Text PDF

Objective: Due to the burden of neurologic disease, there is high demand for neurologists, child neurologists, and neurosurgeons. Only 2.6% of graduating medical students matched in neuromedicine residencies in 2014.

View Article and Find Full Text PDF

Objective: To develop an understanding of the availability of the formal clinical neuro-oncology educational opportunities for medical students.

Methods: The curriculum websites of all medical schools accredited by the Liaison Committee on Medical Education were reviewed for the presence of clinical neuro-oncology electives as well as other relevant data.

Results: Ten (6.

View Article and Find Full Text PDF